Increased Plasma Heparanase Activity in COVID-19 Patients

Increased Plasma Heparanase Activity in COVID-19 Patients

Reports suggest a role of endothelial dysfunction and loss of endothelial barrier function in COVID-19. It is well established that the endothelial glycocalyx-degrading enzyme heparanase contributes to vascular leakage and inflammation. Low molecular weight heparins (LMWH) serve as an inhibitor of h...

Full description

Bibliographic Details
Main Authors: Baranca Buijsers, Cansu Yanginlar, Aline de Nooijer, Inge Grondman, Marissa L. Maciej-Hulme, Inge Jonkman, Nico A. F. Janssen, Nils Rother, Mark de Graaf, Peter Pickkers, Matthijs Kox, Leo A. B. Joosten, Tom Nijenhuis, Mihai G. Netea, Luuk Hilbrands, Frank L. van de Veerdonk, Raphaël Duivenvoorden, Quirijn de Mast, Johan van der Vlag
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Immunology
Subjects:
inflammation
heparanase
LMWH (low molecular weight heparin)
vascular leakage
glycocalyx damage
COVID-19
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.575047/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.575047/full

Similar Items